Less than 1 min.Read

OncoImmune: Raises $56M Series B Financing

September 11, 2020

OncoImmune, Inc., a Rockville, Md.-based clinical-stage biopharmaceutical company, completed a $56m Series B equity financing
The round co-led by HM Capital and a blue-chip investor
Existing investors, 3E Bioventures Capital and Kaitai Capital, as well as additional new investors, GBA Fund and GF Xinde, also joined the round
The company will also use the proceeds to support its novel therapeutic programs in late stage clinical trials and to expand its product pipeline
OncoImmune actively engaged in the discovery and development of novel immunotherapies for cancer, inflammation and autoimmune diseases
Then the company currently has two Phase III clinical programs to evaluate its lead product CD24Fc